India, July 6 -- Invivyd Inc. (IVVD), a pharmaceutical company developing antibody therapies, on Monday announced the receipt of a notice of termination for the emergency use authorization of PEMGARDA in the prevention of COVID-19.
PEMGARDA (pemivibart) is a half-life investigational monoclonal antibody that previously demonstrated in vitro neutralization of major SARS-CoV-2 variants. The drug received an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) in March 2023 and came into use in 2024. According to the EUA, the drug could be utilized in the pre-exposure prophylaxis of COVID-19 for immunocompromised individuals unable to mount an immune reaction against COVID vaccinations.
The EUA termination is vi...